Characterization of the CD30L Binding Domain on the Human CD30 Molecule Using Anti-CD30 Antibodies
- 1 February 2000
- journal article
- research article
- Published by Mary Ann Liebert Inc in Hybridoma
- Vol. 19 (1) , 43-48
- https://doi.org/10.1089/027245700315789
Abstract
CD30 and its counter-receptor CD30 ligand (CD30L) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation. Several monoclonal antibodies (MAbs) have been developed against CD30 and, based on mutual inhibition assays, are grouped into three nonoverlapping serologic clusters. However, the relationship between the epitopes recognized by the antibodies comprising each cluster and the binding domain for CD30L is not known. Using a soluble CD30L/CD8 alpha chimeric protein, we assessed the ability of anti-CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30 + Karpas 299 cell line. CD30L binding by CD30 is blocked by MAb that recognize epitopes belonging to cluster Group A (like Ber-H2, Ber-H8, and HRS-4) as well as cluster Group C (like HeFi-1 and M44). Cluster Group B antibodies, including M67 and Ki-1, do not affect CD30L binding to CD30. The pattern of CD30L binding inhibition shows only limited correspondence to the functional capacity of some anti-CD30 MAb to trigger CD30 signaling. Finally, we demonstrate that the anti-CD30L MAb M81 also completely inhibits CD30/CD30L interaction. This information is useful for applying these MAbs in functional studies to further investigate the CD30/CD30L system and for designing assays for soluble CD30L.Keywords
This publication has 19 references indexed in Scilit:
- Expression of CD30 Ligand (CD153) on Murine Activated T CellsBiochemical and Biophysical Research Communications, 1999
- Construction and expression of a soluble form of human CD30 ligand with functional activityJournal of Leukocyte Biology, 1998
- Tumor Necrosis Factor Receptor-associated Factor (TRAF) 5 and TRAF2 Are Involved in CD30-mediated NFκB ActivationPublished by Elsevier ,1997
- CD30 ligand is expressed on resting normal and malignant human B lymphocytesBritish Journal of Haematology, 1996
- Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-kappabeta transcription factorBlood, 1996
- CD30 Ligand, a Member of the TNF Ligand Superfamily, with Growth and Activation Control for CD30+ Lymphoid and Lymphoma Cells*Leukemia & Lymphoma, 1996
- CD30 ligation induces nuclear factor‐ϰB activation in human T cell linesEuropean Journal of Immunology, 1995
- Regulation of murine B cell growth and differentiation by CD30 ligandEuropean Journal of Immunology, 1995
- Shedding of the soluble form of CD30 from the Hodgkin‐analogous cell line L540 is strongly inhibited by a new CD30‐specific antibody (Ki‐4)International Journal of Cancer, 1995
- Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cellsNature, 1982